MoonLake Immunotherapeutics (MLTX) Other Non Operating Income (2021 - 2026)
MoonLake Immunotherapeutics (MLTX) posted quarterly Other Non Operating Income of -$359000.0 for Q1 2026, down 105.06% year-over-year from $7.1 million in Q1 2025, and down 168.38% quarter-over-quarter from $525000.0 in Q4 2025.
MoonLake Immunotherapeutics (MLTX) Other Non Operating Income (2021 - 2026) Analysis & Trends
MoonLake Immunotherapeutics' Other Non Operating Income history runs 6 years deep, the most recent figure standing at -$359000.0 for Q1 2026.
- In Q1 2026, Other Non Operating Income fell 105.06% year-over-year to -$359000.0; the TTM figure through Mar 2026 stood at $7.0 million (down 31.37% YoY), while the FY2025 annual figure was $641000.0, down 97.1% from the prior year.
- Other Non Operating Income for Q1 2026 stood at -$359000.0, down from $525000.0 in the prior quarter.
- The five-year high for Other Non Operating Income was $7.2 million in Q4 2023, with the low at -$359000.0 in Q1 2026.
- The 5-year median for Other Non Operating Income is $39157.0 (2023), against an average of $1.4 million.
- The sharpest annual moves came in 2022 and 2024: Other Non Operating Income surged 10259.7% in 2022, then sank 396.24% in 2024.
- MoonLake Immunotherapeutics' Other Non Operating Income stood at -$186990.0 in 2022, then soared by 3942.69% to $7.2 million in 2023, then sank by 55.1% to $3.2 million in 2024, then sank by 83.73% to $525000.0 in 2025, then tumbled by 168.38% to -$359000.0 in 2026.
- Business Quant data shows MLTX's Other Non Operating Income at -$359000.0 in Q1 2026, $525000.0 in Q4 2025, and $8000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | MoonLake Immunotherapeutics | 1.40 Bn | 864.68 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.58 Mn |
| Mar 31, 2026 | -359,000.00 |
| Dec 31, 2025 | 525,000.00 |
| Sep 30, 2025 | 8,000.00 |
| Jun 30, 2025 | 6.78 Mn |
| Mar 31, 2025 | 7.10 Mn |
| Dec 31, 2024 | 3.23 Mn |
| Sep 30, 2024 | -116,000.00 |
| Jun 30, 2024 | -76,000.00 |
| Mar 31, 2024 | 81,000.00 |
| Dec 31, 2023 | 7.19 Mn |
| Sep 30, 2023 | 39,157.00 |
| Jun 30, 2023 | -16,336.00 |
| Mar 31, 2023 | -42,144.00 |
| Dec 31, 2022 | -186,990.00 |
| Sep 30, 2022 | 37,593.00 |
| Jun 30, 2022 | 101,597.00 |
| Mar 31, 2022 | 69,506.00 |
| Dec 31, 2021 | -168,177.00 |
| Sep 30, 2021 | 1,000.00 |